Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATx08-001 in Postherpetic Neuralgia
NCT01318226Phase 2Completed
- Sponsor
- Aestus Therapeutics
- Start
- Mar 2011
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of FK-614 in postherpetic neuralgia (PHN) (3 arms), sponsored by Aestus Therapeutics. Primary endpoints: Sum of the Pain Intensity Difference at 6 hours and 12-Hour Pain Intensity Scores at 7 days. Started Mar 2011; status: completed.
02
Drugs
FK-614
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT01318226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01318226.